elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
Atezolizumab
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Atezolizumab
RIS
0.001
(Research Intensity Score)
Papers
74
Top papers
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
2021 · 1497 citations
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
2020 · 1701 citations
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
2023 · 223 citations
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
2025 · 104 citations
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
2026 · 58 citations
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
2020 · 795 citations
ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette–Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)
2025 · 38 citations
The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma
2021 · 297 citations
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial
2025 · 44 citations
Newest papers
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
2026 · 58 citations
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005
2026 · 11 citations
Carboplatin, Etoposide, and Durvalumab for Extensive-Stage Small Cell Lung Cancer in a Patient Undergoing Maintenance Hemodialysis: A Case Report
2026
Emerging therapies and translational advances in small cell lung cancer: Overcoming resistance
2026 · 1 citations
Model‐Based Meta‐Analysis of Overall Survival in Vulnerable Platinum‐Ineligible NSCLC Populations
2026 · 2 citations
Real-world treatment patterns and outcomes of chemo-immunotherapy with or without radiotherapy in extensive-stage small cell lung cancer: the durvalumab expanded access cohort
2026
KẾT QUẢ BƯỚC ĐẦU VÀ TÍNH AN TOÀN CỦA PHÁC ĐỒ ATEZOLIZUMAB KẾT HỢP BEVACIZUMAB TRONG ĐIỀU TRỊ UNG THƯ BIỂU MÔ TẾ BÀO GAN TIẾN XA TẠI BỆNH VIỆN QUÂN Y 175
2026
IZABRIGHT-Bladder01: A randomized, open-label, phase 2/3 trial of izalontamab brengitecan (iza-bren; BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), vs platinum-based chemotherapy (PBC) for patients (pts) with advanced urothelial cancer (aUC) and disease progression on or after immunotherapy.
2026 · 1 citations
Prospective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd‐EOB‐DTPA‐MRI
2026
Browse all papers →
Atezolizumab's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Atezolizumab's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link